MAP2K7 and melanoma: However, either the small number of patients in the BRAF-mutant melanoma subgroup (even though patients were stratified by BRAF mutational status) or the fact that more ipilimumab-assigned patients received subsequent therapy (including anti-PD1 therapies and BRAF and MEK inhibitors) may limit the interpretation of these findings.